Probiotics for Infant Atopic Dermatitis: What the LGG and Perinatal Trials Show

Atopic dermatitis affects roughly 15 to 20 percent of children in high-income countries. The early-life origin of the disease and the role of microbiome maturation in immune development have motivated decades of probiotic trials in pregnant mothers, breastfeeding mothers, and infants. The evidence base is large but heterogeneous, and the major guidelines distinguish carefully between primary prevention (in infants at high atopic risk) and treatment of established eczema.

The Kalliomäki Lactobacillus rhamnosus GG trial

The pivotal trial was Kalliomäki and colleagues 2001, conducted in Finland. Mothers of infants at high familial risk of atopy received Lactobacillus rhamnosus GG (LGG) or placebo for the last four weeks of pregnancy, and the infants then received the same intervention for six months postnatally. By age 2, 23 percent of LGG-treated children had developed atopic dermatitis compared with 46 percent of controls — a relative risk of about 0.5 [1]. The protective effect was largely sustained at age 4 follow-up and partially at age 7, although effect sizes attenuated over time [2].

The replication record

Subsequent trials have produced mixed results. A 2010 trial of LGG by the same Finnish team in a broader (non-high-risk) population did not replicate the protective effect [3]. Trials using other Lactobacillus strains, Bifidobacterium species, or mixed strains have been variable. A 2015 World Allergy Organization meta-analysis concluded that probiotic supplementation in pregnant mothers, breastfeeding mothers, and infants probably reduces incident eczema in high-risk infants, with strain, timing, and exposure-dose effects [4]. The guideline endorsed perinatal probiotic use for primary prevention of eczema in high-risk families but acknowledged that effect sizes are modest and that the optimal strain and duration remain uncertain.

Treatment of established eczema is a different question

A 2018 Cochrane review by Makrgeorgou and colleagues of 39 trials concluded that probiotics make little or no difference for treating eczema once it is established [5]. SCORAD scores, parent-reported symptoms, and quality-of-life measures were not consistently improved by probiotic treatment in children with active atopic dermatitis. This distinction — prevention versus treatment — is essential, and many marketing claims blur it.

Strain specificity and the LGG advantage

Among individual strains, LGG and Lactobacillus rhamnosus HN001 have the strongest primary prevention data. Bifidobacterium lactis BB-12 and Bifidobacterium breve M-16V also have positive trials, often in combination with LGG or HN001. Single-strain Bifidobacterium animalis preparations and Saccharomyces boulardii have not shown atopic prevention effects. Strain-level specificity is genuine and is not interchangeable across products.

Safety in infants

LGG and the other commonly studied strains have an excellent safety profile in healthy term infants. Case reports of probiotic-associated bacteremia exist in premature, immunocompromised, or critically ill infants, and probiotics should not be administered to neonatal intensive-care patients without specific protocol [6]. For term infants in primary prevention trials, no consistent harm has been documented.

Practical guidance

For families with a strong history of atopy (parent or sibling with eczema, asthma, or allergic rhinitis), perinatal LGG starting in the last trimester of pregnancy and continued in the infant through the first six months has the best evidence for reducing eczema incidence. For infants with already-established eczema, probiotic supplementation is unlikely to be a substitute for emollient and topical anti-inflammatory therapy. Discussion with a pediatrician is appropriate before starting any infant supplement.